nach oben

Clinical and Experimental Medicine

Erschienen in:

24.01.2017 | Review Article

Current treatment options of T cell-associated immunotherapy in multiple myeloma

verfasst von: Hailing Liu, Yunbao Pan, Shan Meng, Wanggang Zhang, Fuling Zhou

Erschienen in: Clinical and Experimental Medicine | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Multiple myeloma (MM) is a complex disease and is presently an incurable malignant plasma cell tumor. Although the introduction of proteasome inhibitor and the immunomodulators markedly improved the effect of myeloma therapy, most patients still suffer from relapse even with an initially effective therapy. Accumulating evidence suggests that immunotherapy is a promising option in treating MM. And T cell plays crucial role through inducing sustained immune response in vivo in the immunotherapy of tumors. In this article, we will discuss progress of several T cell-based immunotherapies with insight into how they eradicate myeloma cells and their disadvantages.

Schutt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Muller S, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma. 2006;47(8):1570–82.CrossRefPubMed

Porrata LF, Litzow MR, Markovic SN. Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc. 2001;76(4):407–12.CrossRefPubMed

Southam CM, Brunschwig A, Levin AG, Dizon QS. Effect of leukocytes on transplantability of human cancer. Cancer. 1966;19(11):1743–53.CrossRefPubMed

Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981;41(11 Pt 1):4420–5.PubMed

Michie CA, McLean A, Alcock C, Beverley PC. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature. 1992;360(6401):264–5.CrossRefPubMed

Fujiwara H. Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. Pharmaceuticals (Basel, Switzerland). 2014;7(12):1049–68.CrossRef

Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155(6):1823–41.CrossRefPubMed

Togawa A, Sawada S, Amano M, Oshimi K, Satoh H, Takaku H. Treatment of multiple myeloma with LAK cells plus interleukin 2 or interleukin 2 alone. [Rinsho ketsueki] Jpn J Clin Hematol. 1989;30(5):650–8.

Gottlieb DJ, Prentice HG, Mehta AB, Galazka AR, Heslop HE, Hoffbrand AV, et al. Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. Br J Haematol. 1990;75(4):499–505.CrossRefPubMed

10.

Sun J, Law GP, McKallip RJ. Role of CD44 in lymphokine-activated killer cell-mediated killing of melanoma. Cancer Immunol Immunother CII. 2012;61(3):323–34.CrossRefPubMed

11.

Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4⁺ T cell responses associated with control of viremia. Science. 1997;278(5342):1447–50.CrossRefPubMed

12.

Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995;3:87–98 (J Immunol (Baltimore, Md: 1950). 2010;185(7):3788–99).CrossRefPubMed

13.

Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med. 2005;11(11):1230–7.CrossRefPubMed

14.

Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 2011;117(3):788–97.CrossRefPubMedPubMedCentral

15.

Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(5):1355–65.CrossRef

16.

Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174(1):139–49.CrossRefPubMed

17.

Liu C, Suksanpaisan L, Chen YW, Russell SJ, Peng KW. Enhancing cytokine-induced killer cell therapy of multiple myeloma. Exp Hematol. 2013;41(6):508–17.CrossRefPubMedPubMedCentral

18.

Marten A, Ziske C, Schottker B, Renoth S, Weineck S, Buttgereit P, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother (Hagerstown, Md: 1997). 2001;24(6):502–10.CrossRef

19.

Zhao X, Ji CY, Liu GQ, Ma DX, Ding HF, Xu M, et al. Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy. Int J Clin Exp Pathol. 2015;8(10):13146–55.PubMedPubMedCentral

20.

Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318–21.CrossRefPubMed

21.

Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, et al. CD8⁺ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(24):6122–31.CrossRef

22.

Noonan KA, Borrello IM. Marrow infiltrating lymphocytes: their role in adoptive immunotherapy. Cancer J (Sudbury, Mass). 2015;21(6):501–5.CrossRef

23.

Noonan KA, Huff CA, Davis J, Lemas MV, Fiorino S, Bitzan J, et al. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med. 2015;7(288):288ra78.CrossRefPubMedPubMedCentral

24.

Wen YJ, Min R, Tricot G, Barlogie B, Yi Q. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood. 2002;99(9):3280–5.CrossRefPubMed

25.

Baba T, Hanagiri T, Ichiki Y, Kuroda K, Shigematsu Y, Mizukami M, et al. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Sci. 2007;98(11):1795–802.CrossRefPubMed

26.

Li R, Qian J, Zhang W, Fu W, Du J, Jiang H, et al. Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma. Br J Haematol. 2014;166(5):690–701.CrossRefPubMedPubMedCentral

27.

Bae J, Smith R, Daley J, Mimura N, Tai YT, Anderson KC, et al. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(17):4850–60.CrossRef

28.

Hong S, Lee H, Jung K, Lee SM, Lee SJ, Jun HJ, et al. Tumor cells loaded with alpha-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma. Immunol Lett. 2013;156(1–2):132–9.CrossRefPubMed

29.

Atanackovic D, Luetkens T, Kroger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia. 2014;28(5):993–1000.CrossRefPubMed

30.

Zheng C, Huang D, Liu L, Bjorkholm M, Holm G, Yi Q, et al. Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma. Br J Haematol. 2001;112(1):216–8.CrossRefPubMed

31.

Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA, et al. In vivo peripheral expansion of naive CD4⁺ CD25 high FoxP3⁺ regulatory T cells in patients with multiple myeloma. Blood. 2006;107(10):3940–9.CrossRefPubMed

32.

Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000;83(2):261–6.CrossRefPubMedPubMedCentral

33.

Zitron IM, Thakur A, Norkina O, Barger GR, Lum LG, Mittal S. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC Cancer. 2013;13:83.CrossRefPubMedPubMedCentral

34.

Alvarez-Vallina L, Hawkins RE. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol. 1996;26(10):2304–9.CrossRefPubMed

35.

McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, et al. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol (Baltimore, Md: 1950). 2001;166(10):6112–7.CrossRef

36.

Bhutani D, Lum LG. Activated T cells armed with bispecific antibodies kill tumor targets. Curr Opin Hematol. 2015;22(6):476–83.CrossRefPubMed

37.

Einsele H, Schreder M. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab. Ther Adv Hematol. 2016;7(5):288–301.CrossRefPubMedPubMedCentral

38.

Guidance Development Review C, Working Group for Clinical Studies of Cancer I, Working Group for Effector Cell T, Working Group for CMCN-cS, Working Group for Cancer V, Adjuvants, et al. Guidance on cancer immunotherapy development in early-phase clinical studies. Cancer Sci. 2015;106(12):1761–71.CrossRef

39.

Paiva B, Azpilikueta A, Puig N, Ocio EM, Sharma R, Oyajobi BO, et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia. 2015;29(10):2110–3.CrossRefPubMed

40.

Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol. 2016;9(1):52.

41.

Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31.CrossRefPubMed

42.

Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai YT, Shi J, et al. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep. 2015;12(4):622–35.CrossRefPubMedPubMedCentral

43.

Hoyos V, Borrello I. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies. Blood. 2016;128(13):1679–87.CrossRefPubMed

44.

Karpanen T, Olweus J. T-cell receptor gene therapy–ready to go viral? Mol Oncol. 2015;9(10):2019–42.CrossRefPubMedPubMedCentral

45.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8):914–21.CrossRefPubMedPubMedCentral

46.

Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5(197):197ra03.CrossRef

47.

van Loenen MM, de Boer R, Amir AL, Hagedoorn RS, Volbeda GL, Willemze R, et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci USA. 2010;107(24):10972–7.CrossRefPubMedPubMedCentral

48.

Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90(2):720–4.CrossRefPubMedPubMedCentral

49.

Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Investig. 2011;121(5):1822–6.CrossRefPubMedPubMedCentral

50.

Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J (Sudbury, Mass). 2014;20(2):119–22.CrossRef

51.

Gschweng E, De Oliveira S, Kohn DB. Hematopoietic stem cells for cancer immunotherapy. Immunol Rev. 2014;257(1):237–49.CrossRefPubMedPubMedCentral

52.

Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS ONE. 2013;8(12):e82742.CrossRefPubMedPubMedCentral

53.

Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006;108(12):3890–7.CrossRefPubMedPubMedCentral

54.

Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373(11):1040–7.CrossRefPubMedPubMedCentral

55.

Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(8):2048–60.CrossRef

56.

Luptakova K, Avigan D. Immune therapy in multiple myeloma. Clin Adv Hematol Oncol H&O. 2015;13(11):767–75.

57.

Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T. Chimeric antigen receptor (CAR) therapy for multiple myeloma. Br J Haematol. 2016;172(5):685–98.CrossRefPubMed

58.

Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer. 2005;5:83.CrossRefPubMedPubMedCentral

59.

Meng S, Lu C, Zhang W, Shen W, Wei Y, Su D, et al. MMSA-1 expression pattern in multiple myeloma and its clinical significance. Clin Exp Med. 2016;16(4):599–609.CrossRefPubMed

60.

Zhou F, Meng S, Song H, Claret FX. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention. Blood Rev. 2013;27(6):261–7.CrossRefPubMedPubMedCentral

Titel: Current treatment options of T cell-associated immunotherapy in multiple myeloma
verfasst von: Hailing Liu
Yunbao Pan
Shan Meng
Wanggang Zhang
Fuling Zhou
Publikationsdatum: 24.01.2017
Verlag: Springer International Publishing
Erschienen in: Clinical and Experimental Medicine / Ausgabe 4/2017
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-017-0450-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

26.04.2024 | Hüft-TEP | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Current treatment options of T cell-associated immunotherapy in multiple myeloma

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Platelet-rich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis

High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer

Associations between circulating levels of adipocytokines and abdominal adiposity in patients after acute pancreatitis

Upregulation of ROCK2 in gastric cancer cell promotes tumor cell proliferation, metastasis and invasion

Cycling CD34 expression in subpopulations of head and neck squamous cell carcinoma cell lines is involved in radioresistance and change in cytokeratin expression profile

The use of frozen plasma samples in thromboelastometry

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Update Innere Medizin